Tinlarebant is an oral therapy designed to reduce the accumulation of vitamin A based toxins that cause retinal disease.

A recent paper reveals increasing rates of diabetic retinopathy in young patients with diabetes, sparking concerns over ...

Artificial intelligence has the potential to improve ophthalmology practices by streamlining documentation, enhancing ...

The phase 3 clinical trial is a randomized, double-blind, three-arm study comparing MELT-300, sublingual midazolam, and ...

On World Sight Day, leading experts in ophthalmology look at artificial intelligence and how it could impact diagnosing and ...

MJH Life Sciences, parent company of Ophthalmology Times, has acquired The EnVision Summit. The meeting, held annually in ...

Ten of the institute's ophthalmologists will present their work in more than 20 sessions with a wide range of topics ...

According to the company, a $68 million Series D financing is co-led by Arboretum Ventures and Johnson & Johnson Innovation – ...

According to the company, the platform accompanies the launch of Qdata Retinitis Pigmentosa for life sciences and the ...

Aldeyra Therapeutics has resubmitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for topical ...

Coordinated by the International Agency for the Prevention of Blindness under the Love Your Eyes campaign banner, World Sight ...

The effort represents a consortium of researchers from Penn Medicine, Penn Engineering, the University of Michigan Kellogg ...